My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Reliance Capital gains after board approves independent listing of home finance business

Reliance Capital gains after board approves independent listing of home finance business

Sep 14,2016

The announcement was made yesterday, 13 September 2016, when stock market remained closed on account of Bakri Id.

Meanwhile, the S&P BSE Sensex was down 46.19 points or 0.16% at 28,307.35.

On BSE, so far 6.75 lakh shares were traded in the counter as against average daily volume of 5.01 lakh shares in the past one quarter. The stock hit a high of Rs 561.50 and a low of Rs 546.65 so far during the day. The stock had hit a 52-week high of Rs 574 on 9 September 2016. The stock had hit a 52-week low of Rs 303.60 on 12 February 2016. The stock had outperformed the market over the past one month till 12 September 2016, rising 21.96% compared with 0.71% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 32.06% as against Sensexs 6.45% rise.

The large-cap company has equity capital of Rs 252.63 crore. Face value per share is Rs 10.

Reliance Capital said the independent listing of Reliance Home Finance (RHF) is expected to unlock substantial value for existing shareholders of Reliance Capital. The listing of Reliance Home Finance will also lead to increased management focus and accelerated growth in the home finance business. As per the proposal, 49% stake in Reliance Home Finance Limited will be allotted to all shareholders of Reliance Capital, in the ratio of one share free of cost in Reliance Home Finance for every one share held in Reliance Capital.

Reliance Capital will hold a 51% stake in Reliance Home Finance, and the company will be adequately capitalised to grow the lending book to over Rs 20000 crore in the next 18 months. The proposal is subject to necessary shareholders and other approvals. Reliance Home Finance, a 100% subsidiary of Reliance Capital, provides a wide range of loan solutions like home loan, LAP, construction finance and affordable housing loans. The company reported an AUM of Rs 8259 crore ($1.2 billion) during the quarter ended 30 June 2016.

Mr. Anmol A. Ambani, Director, Reliance Capital said Prime Minister, Narendra Modi has set a goal of affordable housing for all by 2022. There is presently an estimated shortage of 10 crore residential units in India. To address the needs of this sector, Reliance Home Finance has charted an aggressive growth plan in this space, and aims to increase its book size to over Rs 50000 crore in the next few years.

On a consolidated basis, Reliance Capitals net profit rose 3% to Rs 207 crore on 48.3% growth in total income to Rs 3663 crore in Q1 June 2016 over Q1 June 2015.

Reliance Capital, a part of the Reliance Group, is one of Indias leading private sector financial services companies.

Powered by Capital Market - Live News

Jubilant Life Sciences gains on USFDA nod for generic drug
Feb 27,2017

The announcement was made during market hours today, 27 February 2017.

Meanwhile, the S&P BSE Sensex was almost unchanged at 28,893.03.

On the BSE, 63,000 shares were traded on the counter so far as against the average daily volumes of 1.37 lakh shares in the past one quarter. The stock had hit a high of Rs 728 and a low of Rs 704 so far during the day.

The stock had hit a record high of Rs 765 on 7 February 2017 and a 52-week low of Rs 287.20 on 29 February 2016. It had underperformed the market over the past one month till 23 February 2017, gaining 4.7% compared with the Sensexs 6.55% rise. The scrip had also underperformed the market over the past one quarter, advancing 8.83% as against the Sensexs 10.91% rise.

The large-cap company has equity capital of Rs 15.93 crore. Face value per share is Rs 1.

ltraconazole Capsules, 100 mg, is the generic version of Sporanox of Janssen Pharmaceuticals, which is used for the treatment of fungal infections.

Jubilant Life Sciences has received 8 approvals from the United States Food and Drug Administration (USFDA) during the year. As on 31 December 2016, Jubilant Life Sciences had a total of 73 abbreviated new drug application (ANDAs) for oral solids filed in the US, of which 49 have been approved.

On a consolidated basis, Jubilant Life Sciences net profit fell 2.6% to Rs 119.78 crore on 8.7% growth in net sales to Rs 1438.81 crore in Q3 December 2016 over Q3 December 2015.

Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients and drug discovery solutions. The pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma, is engaged in manufacture and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile and non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada.

The life science ingredients segment, is engaged in specialty intermediates, nutritional products and life science chemicals through 5 manufacturing facilities in India. The drug discovery solutions segment, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA.

Powered by Capital Market - Live News

Inox Leisure gains after starting operations of cinema theatre at Jamnagar
Feb 27,2017

The announcement was made on Saturday, 25 February 2017.

Meanwhile, the S&P BSE Sensex was up 29.74 points or 0.1% at 28,922.71.

On the BSE, 21,219 shares were traded in the counter so far as against average daily volume of 21,692 shares in the past one quarter. The stock had hit a high of Rs 246.95 and a low of Rs 237.15 so far during the day. The stock had hit a record high of Rs 292.90 on 2 September 2016. The stock had hit a 52-week low of Rs 184.15 on 29 February 2016.

The stock had underperformed the market over the past one month till 23 February 2017, falling 1.27% compared with the Sensexs 6.55% rise. The scrip had also underperformed the market over the past one quarter, gaining 6.18% as against the Sensexs 10.91% rise.

The small-cap company has equity capital of Rs 96.46 crore. Face value per share is Rs 10.

Inox Leisure said that the theatre taken on a lease basis is located at Jamnagar, Gujarat. The operations started with effect from 24 February 2017. The multiplex cinema theatre has 5 screens and 954 seats.

Inox Leisure is now present in 58 cities with 115 multiplexes, 454 screens and a total seating capacity of 1.15 lakh seats across India.

Inox Leisures consolidated net profit fell 78% to Rs 3.75 crore on 1.2% decline in net sales to Rs 279.22 crore in Q3 December 2016 over Q3 December 2015.

Inox Leisure is the diversification venture of the Inox group into entertainment.

Powered by Capital Market - Live News

Jaiprakash Associates leads gainers on BSEs A group
Feb 27,2017

Jaiprakash Associates jumped 8.19% at Rs 15.99. The stock topped the gainers in A group. On the BSE, 1.26 crore shares were traded on the counter so far as against the average daily volumes of 1.03 crore shares in the past two weeks.

Reliance Defence & Engineering rose 7.88%) at Rs 64.35. The stock was the second biggest gainer in A group. On the BSE, 26.13 lakh shares were traded on the counter so far as against the average daily volumes of 5.67 lakh shares in the past two weeks.

Wockhardt rose 7.09% at Rs 755.55. The stock was the third biggest gainer in A group. On the BSE, 3.9 lakh shares were traded on the counter so far as against the average daily volumes of 2.24 lakh shares in the past two weeks.

Raymond rose 5.59% at Rs 589.75. The stock was the fourth biggest gainer in A group. On the BSE, 3.19 lakh shares were traded on the counter so far as against the average daily volumes of 1.23 lakh shares in the past two weeks.

GMR Infrastructure rose 5.51% at Rs 15.70 . The stock was the fifth biggest gainer in A group. On the BSE, 23.83 lakh shares were traded on the counter so far as against the average daily volumes of 27.07 lakh shares in the past two weeks. The company announced that it has completed strategic debt restructuring of its subsidiary, GMR Chhattisgarh Energy. The announcement was made before market hours today, 27 February 2017.

Powered by Capital Market - Live News

Lupins subsidiary Kyowa Pharmaceutical enters into agreement with Astellas Pharma
Feb 27,2017

Lupin announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co., (Kyowa) and Astellas Pharma Inc. (Astellas) have entered into an agreement providing Kyowa the exclusive right to distribute and promote extended-release tablets of quetiapine fumarate in Japan.

Astellas submitted a new drug application (NDA) with the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder.

When Astellas obtains an approval for the new drug application of extended-release tablets of quetiapine fumarate, based on the agreement, Kyowa will exclusively distribute and promote the products in Japan.

Powered by Capital Market - Live News

Lupins subsidiary Kyowa Pharmaceutical enters into agreement with Astellas Pharma
Feb 27,2017

Lupin announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co., (Kyowa) and Astellas Pharma Inc. (Astellas) have entered into an agreement providing Kyowa the exclusive right to distribute and promote extended-release tablets of quetiapine fumarate in Japan.

Astellas submitted a new drug application (NDA) with the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder.

When Astellas obtains an approval for the new drug application of extended-release tablets of quetiapine fumarate, based on the agreement, Kyowa will exclusively distribute and promote the products in Japan.

Powered by Capital Market - Live News

Board of V-Guard Industries allots equity shares under ESOS
Feb 27,2017

V-Guard Industries announced that the Board of Directors of the Company at its meeting held on 27 February 2017 has allotted 8,71,766 equity shares having face value of Re 1 each to employees who have exercised the stock options under ESOS 2013.

Powered by Capital Market - Live News

Board of V-Guard Industries allots equity shares under ESOS
Feb 27,2017

V-Guard Industries announced that the Board of Directors of the Company at its meeting held on 27 February 2017 has allotted 8,71,766 equity shares having face value of Re 1 each to employees who have exercised the stock options under ESOS 2013.

Powered by Capital Market - Live News

Sahyog Multibase announces cessation of Chairman and MD
Feb 27,2017

Sahyog Multibase announced that Sunil Kumar Kapoor, Chairman and Karan Kapoor, Managing Director of the Company has tendered their resignation from the position of Chairmanship and Directorship of the Company w.e.f. 22 February 2017 respectively.

Powered by Capital Market - Live News

Zydus Nesher Pharmaceuticals receives final approval for Oseltamivir Phosphate Capsules
Feb 27,2017

Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has received final approval from the USFDA to market Oseltamivir Phosphate Capsules, USP in strengths of 30mg, 45mg and 75mg. The drug will be produced at the Nesher Pharmaceutical USA manufacturing facility located in St. Louis, MO, USA. It is an anti-viral used in the prevention and treatment of influenza virus infection. The estimated sales for Oseltamivir Phosphate Capsules is $382 million as per IMS December 2016.

Powered by Capital Market - Live News

Lakshmi Vilas Bank announces cessation of director
Feb 27,2017

Lakshmi Vilas Bank announced that K. R. Pradeep, Director of the Bank has retired on 26 February 2017 pursuant to Section 10A (2A) of the Banking Regulation Act, 1949, having held office as Director continuously for a period of eight years.

Powered by Capital Market - Live News

Pincon Spirit acquires five liquor retail outlets
Feb 27,2017

Pincon Spirit has taken over 5 (Five) numbers Liquor Retails Outlets at different prime locations in Kolkata, an edge towards own brand emerging sales through retail outlets only.

Powered by Capital Market - Live News

Ruby Mills spurts after resuming operations at Khalapur unit
Feb 27,2017

The announcement was made on Friday, 24 February 2017. The stock market was closed on that day due to Mahashivratri holiday.

Meanwhile, the S&P BSE Sensex was up 12.99 points or 0.04% at 28,905.96.

On the BSE, 5,001 shares were traded on the counter so far as against the average daily volumes of 2,152 shares in the past one quarter. The stock had hit a high of Rs 365 and a low of Rs 350 so far during the day.

The stock had hit a 52-week high of Rs 518 on 28 September 2016 and a 52-week low of Rs 250.10 on 29 February 2016. It had underperformed the market over the past one month till 23 February 2017, sliding 1.12% compared with the Sensexs 6.55% rise. The scrip had, however, outperformed the market over the past one quarter, advancing 16.7% as against the Sensexs 10.91% rise.

The small-cap company has equity capital of Rs 8.36 crore. Face value per share is Rs 5.

Ruby Mills announced after market hours on Thursday, 23 February 2017 that the companys processing unit at Khalapur had got permission from Maharashtra Pollution Control Board (MPCB) to restart its operations with immediate effect. Earlier, the company had announced to the stock exchanges that the unit was experiencing disruption of operations due to power shut down by Maharashtra State Electricity Board (MSEB) on 7 February 2017, pursuant to MPCB instructions due to non-operation of common effluent treatment plant (CETP).

Ruby Mills net profit rose 23.3% to Rs 8.04 crore on 16.3% decline in net sales to Rs 41.12 crore in Q3 December 2016 over Q3 December 2015.

Ruby Mills is engaged in textiles business.

Powered by Capital Market - Live News

Lupin gains after Japanese subsidiary enters into agreement with Astellas
Feb 27,2017

The announcement was made during market hours today, 27 February 2017.

Meanwhile, the S&P BSE Sensex was up 9.07 points or 0.06% at 28,911.59.

On the BSE, 58,552 shares were traded on the counter so far as against the average daily volumes of 71,762 shares in the past one quarter. The stock had hit a high of Rs 1,465 and a low of Rs 1,450 so far during the day. The stock had hit a 52-week high of Rs 1,874.30 on 14 March 2016 and a 52-week low of Rs 1,294.05 on 29 March 2016.

The stock had underperformed the market over the past one month till 23 February 2017, falling 1.97% compared with the Sensexs 6.55% rise. The scrip had also underperformed the market over the past one quarter, dropping 2.28% as against the Sensexs 10.91% rise.

The large-cap company has equity capital of Rs 90.30 crore. Face value per share is Rs 2.

Lupin announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co., Ltd. and Astellas Pharma Inc. have entered into an agreement providing Kyowa the exclusive right to distribute and promote extended-release tablets of quetiapine fumarate in Japan.

Astellas submitted a new drug application (NDA) withthe Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for theindication of improvement of depressive symptoms associated with bipolar disorder.

When Astellas obtains an approval for the new drug application of extended-release tablets of Quetiapine fumarate, based on the agreement, Kyowa will exclusively distribute and promote the products in Japan, Lupin said.

Lupins consolidated net profit rose 20.7% to Rs 633.11 crore on 31.5% increase in net sales to Rs 4404.94 crore in Q3 December 2016 over Q3 December 2015.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership position in the anti-TB segment.

Powered by Capital Market - Live News

Meglon Infra-Real (India) to hold board meeting
Feb 27,2017

Meglon Infra-Real (India) will hold a meeting of the Board of Directors of the Company on 7 March 2017.

Powered by Capital Market - Live News

Ruchira Papers gets ratings revision for long term facilities
Feb 27,2017

Ruchira Papers announced that CARE Ratings has upgraded the credit ratings from CARE BBB to CARE BBB+; Stable assigned to long term facilities of the Company and CARE BBB+/ CARE A3+ assigned to short term facilities of the Company.

Powered by Capital Market - Live News